Preferred Label : Trastuzumab Duocarmazine;
NCIt synonyms : Trastuzumab-drug Conjugate SYD985; Antibody-drug Conjugate SYD985; ADC SYD985; Trastuzumab VC-seco-DUBA; vic-Trastuzumab Duocarmazine;
NCIt definition : An antibody-drug conjugate (ADC) composed of the recombinant humanized anti-epidermal
growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable
linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole (seco-DUBA),
with potential antineoplastic activity. Upon administration of trastuzumab duocarmazine,
the trastuzumab moiety binds to HER2 on the tumor cell surface, which triggers the
endocytosis of this agent. The linker is then cleaved inside the tumor cell by proteases
at the dipeptide valine-citrulline (vc), and releases the active moiety, duocarmycin.
Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position,
and induces cell death. In addition, trastuzumab induces antibody-dependent cell-mediated
cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed
by many carcinomas and is associated with a poor prognosis.;
UNII : XCR2BZ80N7;
CAS number : 1642152-40-6;
Molecule name : SYD985;
Origin ID : C118674;
UMLS CUI : C3896762;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
